IRVINE, Calif., Aug. 28, 2012 /PRNewswire/ -- GeneTex, Inc., a leading manufacturer of antibodies, has announced that they will be launching a new antibody against HIF1a (hypoxia-inducible factor 1alpha).
Hypoxia, a physiological state characterized by reduced oxygen levels, impacts metabolism, angiogenesis, vasodilation and erythropoiesis through the HIF1a transcription factor. In addition to being a natural physiological process, hypoxia and the subsequent accumulation of HIF1a have been shown to significantly contribute to the pathophysiology of multiple diseases including cancer, pulmonary hypertension, myocardial and cerebral ischemia, congenital heart disease and chronic obstructive pulmonary disease. When oxygen becomes limited, prolyl hydroxylase is inhibited, which leads to HIF1a accumulation and translocation to the nucleus. HIF1a then activates transcription of various genes including VEGFA, Glut1 and CA9 that are responsible for the cellular hypoxia response. Therefore, antibodies that can accurately detect HIF1a are valuable research tools for the study of hypoxia and hypoxia-related diseases.
"HIF1a is an important target for biomedical research, but unfortunately many of the antibodies that are currently on the market have been plagued by specificity and stability issues," says Dr. Stephen Kendall. "GeneTex's new HIF1a antibody can withstand multiple freeze/thaw cycles without losing its sensitivity."
GeneTex is proud to introduce this superior antibody against HIF1a that is both highly stable and specific. This antibody has been fully validated for immunocytochemistry/immunofluorescence, immunoprecipitation and western blotting applications.
For additional information on GeneTex, Inc. and its hypoxia antibodies, please call toll-free 877-GENETEX (436-3839) or visit http://www.genetex.com/HIF1-alpha-antibody-GTX127309.html.
About GeneTex, Inc.
GeneTex, Inc. is an antibody manufacturer founded by a group of internationally renowned academic scientists in 1997. They strive to produce the highest quality antibodies and reagents. Their primary antibodies and secondary antibodies are created through a process involving extensive research, development and validation. GeneTex's catalog has grown to over 55,000 primary antibodies and all are backed by a 100% Satisfaction Guarantee.
We strive to serve and accelerate life science research by creating essential life science tools where quality can be found in every vial.
|SOURCE GeneTex, Inc.|
Copyright©2012 PR Newswire.
All rights reserved